Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
argenx SE - American Depositary Shares
(NQ:
ARGX
)
875.57
+7.63 (+0.88%)
Streaming Delayed Price
Updated: 9:47 AM EDT, Aug 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about argenx SE - American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
argenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025
October 23, 2025
From
argenx SE
Via
GlobeNewswire
If You Invested $1000 In argenx Stock 5 Years Ago, You Would Have This Much Today
↗
October 22, 2025
Via
Benzinga
Checking In on The Trade Desk, Bristol Myers Squibb, and Other Stocks
↗
October 22, 2025
Motley Fool analysts Karl Thiel, Rick Munarriz, and Tim Beyers offer up three stocks that face dark clouds they can see through.
Via
The Motley Fool
Topics
Workforce
argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session
October 15, 2025
From
argenx SE
Via
GlobeNewswire
How Do Investors Really Feel About argenx SE?
↗
October 13, 2025
Via
Benzinga
12 Analysts Have This To Say About argenx
↗
September 18, 2025
Via
Benzinga
Assessing argenx: Insights From 12 Financial Analysts
↗
October 13, 2025
Via
Benzinga
Tesla To $300? Here Are 10 Top Analyst Forecasts For Monday
↗
October 13, 2025
Via
Benzinga
argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025
October 03, 2025
From
argenx SE
Via
GlobeNewswire
ARGENX SE - ADR (NASDAQ:ARGX) Matches a Proven Growth Stock Strategy
↗
October 03, 2025
ARGENX stock matches a proven growth strategy, showing explosive earnings revisions, 731% EPS growth, and strong revenue momentum.
Via
Chartmill
Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today
↗
September 29, 2025
argenx (NASDAQ: ARGX) has outperformed the market over the past 5 years by 7.61% on an annualized basis producing an average annual return of 22.36%. Currently, argenx has a market capitalization of...
Via
Benzinga
Is argenx Gaining or Losing Market Support?
↗
September 08, 2025
Via
Benzinga
Assessing argenx: Insights From 11 Financial Analysts
↗
August 25, 2025
Via
Benzinga
Price Over Earnings Overview: argenx
↗
September 26, 2025
In the current market session, argenx Inc. (NASDAQ: ARGX) share price is at $711.62, after a 0.07% increase. Moreover, over the past month, the stock decreased by 0.08%, but in the past year, went up...
Via
Benzinga
Pharma Tariffs Back In Spotlight On New Trump Threat
↗
September 26, 2025
President Donald Trump threatened 100% tariffs on some drug imports.
Via
Investor's Business Daily
Topics
ETFs
Government
World Trade
Johnson & Johnson Unleashes Triple Threat: Bladder Cancer Breakthrough, Psoriasis Game-Changer, and Myasthenia Gravis Milestone Signal New Pharma Era
September 19, 2025
Johnson & Johnson (NYSE: JNJ) is making significant waves in the pharmaceutical landscape, announcing a trio of pivotal developments that underscore its robust pipeline and strategic focus on unmet...
Via
MarketMinute
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today
↗
September 10, 2025
Via
Benzinga
argenx SE - ADR (NASDAQ:ARGX) Fits Louis Navellier's 'Little Book' Growth Strategy
↗
September 10, 2025
Discover argenx SE (ARGX), a top growth stock meeting Louis Navellier's strict criteria with surging earnings, 97% revenue growth, and strong profitability.
Via
Chartmill
United Therapeutics Price Strength Rating Jumps After Its Stock Soared 33% Last Week On Positive Drug Test Results
↗
September 10, 2025
United Therapeutics also boasts a terrific 96 Composite Rating. The Composite score combines five separate proprietary ratings into one.
Via
Investor's Business Daily
Topics
ETFs
Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again
↗
September 08, 2025
The company is working on a treatment for an autoimmune disease that affects the muscles.
Via
Investor's Business Daily
3 Healthcare Pathbreakers With Long-Term Tailwinds
↗
September 01, 2025
These three firms in the fast-changing healthcare sector stand out to analysts for their strong product lineups, defensible technology, and notable pipelines.
Via
MarketBeat
argenx to Present at Upcoming Investor Conferences
August 28, 2025
From
argenx SE
Via
GlobeNewswire
Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today
↗
August 27, 2025
Via
Benzinga
Argenx Immune Disorder Drug's Reach Could Get Much Bigger With Major Trial Win
↗
August 26, 2025
Argenx advances Vyvgart with strong trial data in seronegative gMG, driving growth projections and reinforcing its leadership in IgG-driven diseases.
Via
Benzinga
Regeneron Advances In Rare Disease Race With Positive Autoimmune Muscle Disorder Trial Data
↗
August 26, 2025
Regeneron's Phase 3 NIMBLE trial showed cemdisiran improved myasthenia gravis symptoms, with an FDA filing expected in early 2026.
Via
Benzinga
Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded
↗
August 26, 2025
Additionally, the IBD SmartSelect Composite Rating for Argenx stock rose from 94 to a near best 96 Tuesday.
Via
Investor's Business Daily
Topics
ETFs
Argenx Tops Buy Point On Bullish Study, 850 Price Target
↗
August 25, 2025
Argenx announced positive study results and plans to seek FDA approval to expand its label for Vyvgart. ARGX stock jumped as RBC initiated coverage.
Via
Investor's Business Daily
Argenx Targets FDA Label Expansion After Vyvgart Trial Success
↗
August 25, 2025
Argenx reported positive Phase 3 Vyvgart data in seronegative myasthenia gravis, with plans for an FDA filing to expand the drug's label in 2025
Via
Benzinga
argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG
August 25, 2025
From
argenx SE
Via
GlobeNewswire
ARGENX SE - ADR (NASDAQ:ARGX) Ticks Key Boxes for Growth Investors Using Navellier's 'Little Book' Strategy
↗
August 19, 2025
Discover ARGX, a top growth stock matching Navellier's criteria with explosive earnings growth, soaring sales, and a high 21% ROE.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
